Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
IPO Year:
Exchange: NYSE
Website: bd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/1/2024 | $255.00 → $275.00 | Neutral → Buy | Citigroup |
| 5/30/2024 | $274.00 | Buy | Goldman |
| 7/24/2023 | $305.00 | Mkt Perform → Outperform | Raymond James |
| 5/30/2023 | $295.00 | Overweight | Morgan Stanley |
| 5/5/2023 | $260.00 → $290.00 | Neutral → Overweight | Piper Sandler |
| 4/12/2023 | $304.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 1/3/2023 | $250.00 → $290.00 | Neutral → Buy | BofA Securities |
| 12/12/2022 | $221.00 → $250.00 | Sell → Neutral | Citigroup |
| 7/11/2022 | $265.00 → $235.00 | Neutral → Sell | Citigroup |
| 6/24/2022 | $275.00 | Equal Weight → Overweight | Wells Fargo |
FRANKLIN LAKES, N.J., Jan. 16, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, February 6, 2025 to discuss the Company's financial results for its first quarter of fiscal year 2025, which ended on December 31, 2024, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that wil
83% Want More Accessible and Less Invasive Testing Options MISSISSAUGA, ON, Jan. 15, 2025 /CNW/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced the results of a new survey revealing that 74% of women in Canada have delayed a gynecology visit, with 83% wanting more accessible and less invasive cervical cancer testing options, including at-home self-collection for human papillomavirus (HPV) tests. In an online survey conducted by The Harris Poll involving more than 500 adult women in Canada, it was found that while 69% of
FRANKLIN LAKES, N.J., Jan. 15, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced additional investments in its U.S. manufacturing network to add capacity for critical medical devices, including syringes, needles and IV catheters, to meet the ongoing needs of the nation's health care system. As part of the company's 2024 investment of more than $10 million to expand manufacturing capacity, new needle and syringe production lines have been installed at the BD plants in Connecticut and Nebraska. One li
BD Onclarity™ HPV assay adheres to new guidelines by identifying more individual types of HPV than any other test on the market FRANKLIN LAKES, N.J., Jan. 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that the BD Onclarity™ HPV Assay has officially been added to the American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines, due to its ability to individually identify more high-risk types of HPV. The new guidelines represent a significant step fo
FRANKLIN LAKES, N.J., Jan. 10, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that Pamela Spikner has been named senior vice president, chief accounting officer and controller, effective January 20. In this role, Spikner will be responsible for all accounting policy and financial reporting for the company. She will report to Chris DelOrefice, executive vice president and chief financial officer. "Pam has a proven track record of leadership in corporate finance and accounting, with a deep passion
Women Are Seeking More Convenience and Less Discomfort in Testing Options FRANKLIN LAKES, N.J., Jan. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the results of a new survey, revealing that 72% of women in the United States have delayed having a gynecology visit, with many highlighting the need for greater convenience, comfort and ease for this critical cervical cancer screening process. According to the survey, conducted online by The Harris Poll among over 1,100 adult women in the U.S. in
FRANKLIN LAKES, N.J., Jan. 7, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will host its virtual 2025 Annual Meeting of Shareholders (the "Annual Meeting") on Tuesday, January 28, 2025, at 1:00 p.m. (ET). As described in the proxy materials for the Annual Meeting previously distributed, shareholders as of the close of business on December 9, 2024, or their duly authorized proxies, will be able to attend and participate in the Annual Meeting, vote their shares and ask questions by visiting https://meetnow.global/M5X7D4A. Guests may also access the Annual Meeting but in listen-only mode. No control num
FRANKLIN LAKES, N.J. and AUSTIN, Texas, Dec. 17, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care technology company, today announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctor offices and other ambulatory care settings. This innovative blood testing process integrates BD's MiniDraw™ Capillary Blood Collection System with Babson's Better
FRANKLIN LAKES, N.J., Dec. 16, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today issued the following statement: BD has reached an agreement with the U.S. Securities and Exchange Commission (SEC) to resolve the previously disclosed investigation related to prior public disclosures and SEC reporting regarding the BD Alaris™ System, which was acquired by BD from CareFusion in 2015 and is part of the BD Medication Management Solutions business. The SEC Order, the findings of which BD neither admits nor denies, r
SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4/A - BECTON DICKINSON & CO (0000010795) (Issuer)
4/A - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
4 - BECTON DICKINSON & CO (0000010795) (Issuer)
For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa
For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
DEFA14A - BECTON DICKINSON & CO (0000010795) (Filer)
DEF 14A - BECTON DICKINSON & CO (0000010795) (Filer)
10-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
10-Q - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
8-K - BECTON DICKINSON & CO (0000010795) (Filer)
Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organicQ4 GAAP and adjusted diluted EPS from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectivelyFY24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organicFY24 GAAP and adjusted diluted EPS from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectivelyFY24 cash from continuing operations grew 28.5% to $3.8 billion and Free Cash Flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively
FRANKLIN LAKES, N.J., Nov. 7, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of $1.04 per common share, an increase of 9.5% from the previous quarter. The dividend will be payable on December 31, 2024 to holders of record on December 9, 2024. The indicated annual dividend rate for fiscal year 2025 is $4.16 per share. "This is the 53rd consecutive fiscal year in which we have raised our dividend, maintaining BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years," said Tom Polen, chairman, CEO and president of BD. "This inc
Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision toolsCombination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilitiesBusiness renamed as BD Advanced Patient Monitoring, will be based in Irvine, Calif. and become part of BD Medical segmentKatie Szyman will continue to lead BD Advanced Patient Monitoring as worldwide presidentFRANKLIN LAKES, N.J., Sept. 3, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technolo
Strong Margin Execution Drives Performance in Quarter Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic revenue growthGAAP and adjusted diluted EPS of $1.68 and $3.50 grew 23.5% and 18.2%, respectivelyYear-to-date Cash from Continuing Operations grew 60% to $2.7 billion and Free Cash Flow grew over 100% to $2.2 billion, increasing $1.0 billion and $1.2 billion since the prior year, respectivelyThe company updated its fiscal 2024 GAAP revenue growth guidance to approximately 3.7%, and its organic revenue growth guidance to 5.0% to 5.25%The company increased its fiscal 2024 adjusted diluted EPS guidance by 5 cents at the midpoint to $13.05 to $13.1
FRANKLIN LAKES, N.J., July 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on September 30, 2024 to holders of record on September 9, 2024. The indicated annual dividend rate is $3.80 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that he
Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organicQ2 GAAP and adjusted diluted EPS of $1.85 and $3.17 grew 20.9% and 10.8%, respectivelyYear-to-date Cash from Continuing Operations of $1.4 billion and Free Cash Flow of $1.1 billion increased $785 million and over $900 million, respectivelyCompany raises full-year adjusted EPS guidance and affirms organic revenue growth guidanceFRANKLIN LAKES, N.J., May 2, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its second quarte
FRANKLIN LAKES, N.J., April 30, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on June 28, 2024 to holders of record on June 10, 2024. The indicated annual dividend rate is $3.80 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advan
Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q1 revenue of $4.7 billion increased 2.6% as reported, 1.6% currency-neutral and 2.4% organicQ1 GAAP and adjusted diluted EPS from continuing operations of $0.96 and $2.68, respectivelyCompany raises full-year adjusted EPS guidance and midpoint of organic revenue growth guidanceFRANKLIN LAKES, N.J., Feb. 1, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its first quarter of fiscal 2024, which ended December 31, 2023. "Our Q1 results reflect our team's strong execution of our BD 2025 strategy, in particular lev
FRANKLIN LAKES, N.J., Jan. 23, 2024 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $0.95 per common share, payable on March 29, 2024 to holders of record on March 8, 2024. The indicated annual dividend rate is $3.80 per share. About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advan
Continues Strong Performance and Progress Toward Achieving BD 2025 Strategy; Advances Innovation Pipeline and Receives Clearance for Updated BD Alaris™ Infusion System Revenue of $4.9 billion increased 5.1% as reported and 6.3% on a currency-neutral basisRevenue from base business (which excludes COVID-only diagnostic testing) grew 6.7% as reported, 7.9% currency-neutral or 6.3% organicGAAP and adjusted diluted EPS from continuing operations of $1.36 and $2.96, respectivelyCompany raises full-year base organic revenue growth guidance; maintains full-year adjusted EPS guidanceFRANKLIN LAKES, N.J., Aug. 3, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global med
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
SC 13G/A - BECTON DICKINSON & CO (0000010795) (Subject)
Citigroup upgraded Becton Dickinson from Neutral to Buy and set a new price target of $275.00 from $255.00 previously
Goldman initiated coverage of Becton Dickinson with a rating of Buy and set a new price target of $274.00
Raymond James upgraded Becton Dickinson from Mkt Perform to Outperform and set a new price target of $305.00
Morgan Stanley resumed coverage of Becton Dickinson with a rating of Overweight and set a new price target of $295.00
Piper Sandler upgraded Becton Dickinson from Neutral to Overweight and set a new price target of $290.00 from $260.00 previously
KeyBanc Capital Markets upgraded Becton Dickinson from Sector Weight to Overweight and set a new price target of $304.00
BofA Securities upgraded Becton Dickinson from Neutral to Buy and set a new price target of $290.00 from $250.00 previously
Citigroup upgraded Becton Dickinson from Sell to Neutral and set a new price target of $250.00 from $221.00 previously
Citigroup downgraded Becton Dickinson from Neutral to Sell and set a new price target of $235.00 from $265.00 previously
Wells Fargo upgraded Becton Dickinson from Equal Weight to Overweight and set a new price target of $275.00
SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have
Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply
Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /CNW/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
Zeus, a leading supplier of custom polymer components to the world's most innovative medical device and industrial companies, names Padraic "Paddy" O'Brien as new CEO O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership O'Brien currently serves as Worldwide President of BD Peripheral InterventionORANGEBURG, S.C., March 14, 2024 /PRNewswire/ -- Zeus, the world's leading polymer extrusion and catheter design manufacturer, is excited to announce the appointment of Padraic "Paddy" O'Brien as Chief Executive Officer, effective April 1, 2024. O'Brien joins Zeus at a pivotal moment as the company enters a new chapter of growth under EQT ownership.
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio
Industry Veteran Herman Cueto Named CFO Azenta CFO Lindon Robertson to Retire Company Reaffirms Guidance for Fourth Quarter Fiscal 2023 BURLINGTON, Mass., Sept. 26, 2023 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Herman Cueto will join Azenta as Executive Vice President and Chief Financial Officer, effective October 16. Mr. Cueto, who comes from BD ((Becton, Dickinson and Company, NYSE:BDX), will succeed Azenta CFO Lindon Robertson, who is retiring and will remain as an advisor to facilitate a seamless transition. Steve Schwartz, Azenta President and Chief
FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors. Waldstreicher, 63, was most recently the chief medical officer for Johnson & Johnson (J&J), serving in this capacity from 2012 until her retirement in 2023. As chief medical officer, she provided visionary strategic and operational leadership at J&J, with global responsibility for safety, epidemiology, regulatory and clinical operations transformatio
FRANKLIN LAKES, N.J., Jan. 6, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that Michelle Quinn has been named acting general counsel of BD, succeeding Samrat (Sam) Khichi, who has informed the company of his intent to depart BD for a new opportunity, effective Feb. 3, 2023. Quinn, 54, will be responsible for leading the Law Group at BD. She will report to Tom Polen, chairman, CEO and president of BD and become a member of the BD Executive Leadership Team. Quinn joined BD in 2019 and currently s
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15, 2022. In addition, Story will be a member of the Nominating and Corporate Governance Committee of the Board. Story joins the LivaNova Board with more than 20 years of experience in the global medical technology industry. She currently serves as Worldwide President, Integrated Diagnostic Solutions at BD (Becton, Dickinson and Company) a position she assumed in April 2021. Prior to that, she spent 15 years at Medtronic, where she held a variety of roles in finance, sales and business unit leader
Mike Garrison Named EVP and President, Medical segmentRick Byrd Named EVP and President, Interventional segmentFRANKLIN LAKES, N.J., Aug. 25, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of two senior leaders to segment president roles. Michael (Mike) Garrison has been named executive vice president (EVP) and president of the Medical segment, and Richard (Rick) Byrd has been named executive vice president (EVP) and president of the Interventional segment, both effective Sept. 6.